Search

The literature review evaluates the rehabilitation measures in the country's oncological institutions, assesses regulations in other countries, and scientific publications related to the rehabilitation of cancer patients. Studies were analysed using electronic databases PubMed, Medline, Science Direct, Scopus, Web of Science, e-Library, RSL. Over 47,900 sources were found, of which 50 papers over the past ten years were selected and included in the article. The criteria for inclusion were the rehabilitation of cancer patients, stages of rehabilitation, pre-rehabilitation, nutritional support, psychological assistance, and quality of patients’ life. Considering the urgency of the problem, WHO 2017 took the initiative and adopted the Rehabilitation 2030 program, which provides expanding global access to high-quality rehabilitation as an essential health service for people with non-communicable diseases. According to summarized data, rehabilitation is based on the following principles: stage-by-stage process, consistency, complexity, and individual approach. The stages of medical rehabilitation of cancer patients include pre-rehabilitation; stage I – a period of specialized treatment; stage II – rehabilitation in a hospital setting after discharge; and stage III – early and late rehabilitation periods. An analysis of the situation in Tajikistan showed that in oncology-related institutions, rehabilitation of cancer patients is carried out within the framework of existing protocols for individual nosology, where a set of measures for the stages of rehabilitation is not sufficiently developed. A practical assessment of the effectiveness of rehabilitation is not set up. The stereotype about limiting the use of physiotherapy and sanatorium-resort treatment for cancer patients persists. There are no regulations for comprehensive rehabilitation of cancer patients. The need to optimize treatment results, prolong the survival of patients with various functional disorders, and improve the quality of life dictates the necessity for the development and systematic implementation of comprehensive rehabilitation of cancer patients.

Introduction. Urinary tract infections are among the most frequently seen bacterial infections. Worldwide, about 150 million people are diagnosed with urinary tract infections each year, costing the global economy in excess of 3.5 billion US dollars. Urinary tract infections occur more frequently and exhibit more severe symptoms in cancer patients than in patients with other diseases. Material and methods. The paper analyzes the etiology of urinary tract infections in cancer patients during their stay in the hospital. Results. The presented data concern antibiotic-resistant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). Comparative data on the sensitivity to different antibiotics were shown. Recommendations for treatment aimed at reducing the selective pressure of certain groups of antibiotics, in particular carbapenems, were given.

Cancer is a risk factor for thrombotic complications, while activation of the hemostatic system contributes to the growth and metastasis of the tumor tissue. The paper presents the modern ideas of the pathogenetic features of the interaction of the hemostatic system and immune systems in terms of tumor growth. First category of such factors we refer to as "specific tumor-dependent", the second – as "general pathological risk factors", the third – as "therapy-dependent" risk factors. Pathogenesis of interaction "hemostatic system – tumor tissue – immune system" includes factors related to the response to the tumor: inflammation, acute phase reaction, dysproteinemia, focal necrosis, hemodynamic abnormalities, as well as specific factors caused by the tumor cells and tumor-associated macrophages. Namely: procoagulant and fibrinolytic activity of cancer cells and their interaction with platelets, mononuclear macrophages and endothelium, angiogenesis, iatrogenic aspects (chemoherapy, hormone therapy). Tumor cells activate the coagulation cascade or fibrinolysis system, providing conditions for its further spread, stimulation of angiogenesis, increased vascular permeability, which in turn promotes metastasis.

Introduction. Since 2002, the pharmaceutical care of the cancer patients in Ukraine is carried out centrally by public funds in the framework of the target program "Oncology." In a chronic shortage of funds in the national health care system, as well as taking into account the perspectives of the introduction of the social model of obligatory medical insurance (OMI), enhanced the importance of research on the development of rational mechanisms for the use of public funds, which are sent to drug purchases. Given the high mortality rate among cancer patients, especially in children in Ukraine, these works are of particular socio-economic importance. The aim of work. To study drug purchases that are made for cancer patients in Ukraine in order to identify the main problems and directions of rational scientific basis for the use of public funds in terms of lack of resources in health care, as well as from the perspectives of the introduction of the social model of OMI in Ukraine. Materials and methods. Objects of research: data from the National Cancer Registry, annual plans and registers of public drug procurement Ministry of Ukraine. The paper used data from national legislative and regulatory framework governing the organization of pharmaceutical support cancer patients, standard methods of statistical processing of the dynamics of the clinic-economic analysis. Results and discussion. During 2010-2013 marked increase in the amounts of permanent drug purchases for cancer patients, which is on the growth rate did not meet the dynamics of changes in the relevant during epidemiological indicators. The results integrated ABC/VEN-analysis found no drug purchasing products from the group N and with the status A/V, and the dominance of the number of agents with the status items C/V. The main volume of financial resources was directed to the purchase of drugs from the group E (84.8% - 92.4%) and the status of A/E (78,9% -79,8%), as well as drug belonging to the group L01X - Other antineoplastic agents, (64.8% - 72.4%). During 2010-2013 there is a significant proportion of the fluctuation of the value of the groups of drugs В (in the status В/V and В/E), V (in the status В/V and C/V), E (in the status В/E and C/E). This indicates a lack of evidence-based approaches to determining the need for the acquisition and purchase volumes for the budget. In addition, the statutes disproportionately relative to all groups of oncohematological patients, the distribution of funds for the procurement of drugs. Stable priority position on the amount of purchases (63.5% - 71.2%) took five drugs (bortezomib 3.5 mg, imatinib 400 mg, nilotinib 200 mg, rituximab 500 mg, fludarabine 50 mg), which in most cases, are used in the treatment of chronic forms of leukemia and lymphoma. Conclusions. The results of these studies provide an opportunity to argue about the need to develop and implement the state target program "Hematology." The most important condition for the effective implementation of this program in the functioning of the social model is the introduction of OMI of evidence-based model provide pharmaceutical oncohematological patients according to their actual needs in the various denominations of drugs, as well as the financial capacity of the national health system.